Represents the Third Innovus Pharma Product Notification in the EU
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty
pharmaceutical company engaged in the commercialization, licensing and
development of safe and effective non-prescription medicine and consumer
care products to improve men’s and women’s health and vitality and
respiratory diseases, announced today that it received the CPNP
notification number required to commercialize Zestra Glide® in all 28
member countries of the European Union. This represents the third
Innovus Pharma product to receive CPNP notification in the European
Union in the last two months, the others being for Zestra® and Sensum+®.
“We are pleased to expand the commercialization market for Zestra Glide®
to the European Union,” said Innovus Pharma CEO Dr. Bassam Damaj.
“Combined with our recent announcements of notifications to
commercialize Zestra® and Sensum+® in the EU, we are excited to offer
these three additional products to potential partners in the region to
help us expand Innovus Pharma’s product sales in this, the second
largest market in the world.”
Zestra Glide® is currently exclusively partnered with Orimed Pharma in
Canada, Sothema Labs in the Middle East and North Africa, Elis Pharma in
Turkey and certain select markets, Oz Biogenics in Myanmar and Vietnam,
and KLabs in India.
Zestra Glide® is currently approved in 32 countries and marketed and
sold in three countries, including the United States, Canada and Morocco.
About Zestra Glide® and the Lubricant Market
Zestra Glide® is the only water-based clinically tested lubricant with
high viscosity. Increased viscosity usually translates into longer
effects. The lubricant market is estimated to be around $200 million in
the U.S. (Symphony IRI Group Study, 2012).
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which the Company markets directly; (b) commercial
partners to primary care physicians, urologists, gynecologists and
therapists; and (c) directly to consumers through its on-line channels,
retailers and wholesalers. The Company is dedicated to being a leader in
developing and marketing new OTC and branded Abbreviated New Drug
Application (“ANDA”) products. The Company is actively pursuing
opportunities where existing prescription drugs have recently, or are
expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com;
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the sale of the Zestra Glide® product in
Europe, the sale of other of the Company’s products, projected online
subscribers, estimated market for its products, and statements about
achieving its other development, growth, commercialization, financial
and staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could
differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company’s
most recent filing on Form S-1, annual report on Form 10-K, and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.
Kevin Holmes, 410-825-3930